

EVQ Nano CEO Shaun Rothwell Discusses Advanced Antimicrobial Solution EVQ-218 and Its Impact on AMR

06 November 2024 | News | By Ankit Kankar | ankit.kankar@mmactiv.com

EVQ-218's innovative non-ionic silver nanoparticle mechanism targets antibiotic-resistant pathogens without triggering antimicrobial resistance, offering promising applications in healthcare.



In an insightful interview with **BioSpectrum Asia**, **Shaun Rothwell, CEO of EVQ Nano**, reveals the transformative potential of EVQ-218, a next-generation antimicrobial solution developed to tackle antibiotic-resistant infections. Unlike conventional silver nanoparticles, EVQ-218 employs a unique non-ionic mechanism that eliminates harmful bacteria from within, sidestepping the pathways that typically lead to antimicrobial resistance (AMR). Rothwell explains how EVQ-218's ultrastable shell structure enhances safety and efficacy, its effectiveness against top antibiotic-resistant pathogens, and its promising applications in treating cystic fibrosis-related pulmonary infections and preventing catheter-associated infections.

Q: How does EVQ-218's non-ionic silver nanoparticle mechanism avoid triggering antimicrobial resistance?

EVQ-218 has been characterized as a new form of silver by the *Journal of the American Chemical Society*, [ACS Omega](#). Unlike conventional antibacterial agents and nanosilvers that often trigger antimicrobial resistance (AMR) by rupturing bacterial cell walls, EVQ-218 employs a novel mechanism of action that kills bacteria from the inside.¹ Here's how it works:

- EVQ-218 infiltrates the bacterial cell and begins sequestering sulfur. This neutralizes the cell's energy source, disabling metabolic pathways and destroying the cell from the inside.
- With death of the bacteria and no cell wall damage, warning signals are not sent to adjacent and/or sibling bacteria, preventing bacterial proliferation and AMR.

- In contrast, nanoparticles with silver ions rupture cell walls, triggering activation of AMR pathways.

Q: What makes EVQ-218 effective against the top six antibiotic-resistant pathogens identified by the WHO?

EVQ-218 is the first stable, nonemissive, pure silver nanoparticle. Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering AMR, opening opportunity for widespread therapeutic use.

Q: How does the ultrastable shell structure of EVQ-218 contribute to its safety and efficacy?

The ultrastable shell structure completely inhibits ion emission — a first for a pure metal nanoparticle. The ions in traditional silver have hindered its medical applications due to toxicity risks and limited stability. With its non-ionic properties, EVQ-218 delivers effective antimicrobial action free of cytotoxicity.¹

Q: What advantages does EVQ-218 offer over traditional silver-based antimicrobial therapies?

EVQ-218 meets the highest standards set by the National Institute of Standards and Technology (NIST) while avoiding the limitations and safety risks of other nanosilvers. EVQ-218 nanoparticles demonstrate greater stability, exhibit a true “bare” surface chemistry, and are less likely to degrade or transform compositionally over time.¹

Q: Can you elaborate on the potential impact of EVQ-218 in treating pulmonary bacterial infections in cystic fibrosis patients?

EVQ Nano received two grants from the Cystic Fibrosis Foundation to help develop and test an inhaled therapeutic using EVQ-218 to eliminate bacterial growth in the lungs. In vitro studies found EVQ-218 demonstrated efficacy against pathogens linked to pulmonary infections. In vivo studies conducted to date demonstrate early safety and toxicity data, generating an initial safety profile of EVQ-218:

- Killed 64 strains from nine known drug-resistant bacteria, including *Pseudomonas*, *Burkholderia*, MSSA, MRSA, NTM, *Achromobacter*, and *Stenotrophomonas*.
- Showed efficacy against 14 biofilms tested.
- Eradicated multiple yeast and filamentous fungi.
- Exhibited no toxicity in lung epithelial cells.
- No observable histopathologic findings.
- Developed no bacterial resistance during 28-day testing assay. Resistance to other antibiotics typically occurs in 4-5 days.²⁻⁶

Q: How is EVQ-218 being applied in collaborations with catheter manufacturers to reduce healthcare-associated infections?

The majority of healthcare-associated infections (HAIs) are associated with indwelling devices, with catheter-associated urinary tract infections (CAUTIs) representing the most common type.⁷ Rising antimicrobial resistance has compounded this health threat — as up to one-third of CAUTIs in the U.S. are drug resistant.⁸

In collaboration with leading catheter manufacturers, extensive lab testing on catheters, luers, and fittings manufactured with EVQ-218 nanoparticles infused throughout the polymer, demonstrated:

- Strong antibacterial, antifungal, and antibiofilm efficacy
 - *Staphylococcus aureus*: 7-8 log reduction
 - *Pseudomonas aeruginosa*: 6-7.5 log reduction
 - *Candida albicans*: 5-6.5 log reduction
- Broad-spectrum activity against 64 bacterial strains tested
- No degradation of antimicrobial activity; sustained presence for the life of the product??

References

Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. *ACS Omega*. 2024;9(7):7891-7903. doi: 10.1021/acsomega.3c07745

Cakic M, Glisic S, Nikolic G. Synthesis, characterization and antimicrobial activity of dextran sulphate stabilized silver nanoparticles. *J Mol Struct*. 2016;1110:156–161. doi: 10.1016/j.molstruc.2016.01.040

Yan X, He B, Liu L, Qu G, Shi J, Hu L, Jiang G. Antibacterial mechanism of silver nanoparticles in *Pseudomonas aeruginosa*: Proteomics approach. *Metalomics*. 2018;10:557–564. doi: 10.1039/C7MT00328E

Gamboa SM, Rojas ER, Martínez VV, Vega-Baudrit J. Synthesis and characterization of silver nanoparticles and their application as an antibacterial agent. *Int J Biosen Bioelectron*. 2019;5(5):166-173. doi: 10.15406/ijbsbe.2019.05.00172

Rajeshkumar S, Bharath LV. Mechanism of plant-mediated synthesis of silver nanoparticles—A review on biomolecules involved, characterisation and antibacterial activity. *Chem Biol Interact*. 2017;273:219–227. doi: 10.1016/j.cbi.2017.06.019

Mikhailova EO. Silver nanoparticles: mechanism of action and probable bio-Application. *J Funct Biomater*. 2020 Dec; 11(4): 84. Published online 2020 Nov 26. doi: 10.3390/jfb11040084

Health Care-Associated Infections. Patient Safety Network. Published September 7, 2019. Accessed November 21, 2023. <https://psnet.ahrq.gov/primer/health-care-associated-infections>

Werneburg GT. Catheter-associated urinary tract infections: current challenges and future prospects. *Res Rep Urol*. 2022; Apr 4;14:109-133. doi: 10.2147/RRU.S273663. PMID: 35402319; PMCID: PMC8992741